Seer, Inc. (SEER) Balance Sheet

The steady reduction in total assets, coupled with the persistent accumulation of negative retained earnings, indicates a business model that is currently failing to generate the internal capital necessary to maintain its scale. Investors should monitor whether this asset liquidation trend accelerates as the company attempts to navigate its current commercial adoption challenges.

While the current ratio remains high at 17.73, this metric is likely distorted by the company's specific asset composition and does not fully capture the urgency of the cash burn. The lack of consistent cash generation implies that the company may soon face the necessity of dilutive financing to maintain its current research and commercial infrastructure.

The consistent expansion of negative retained earnings, which reached -$482.8M in 2026Q1, highlights the structural difficulty the company faces in achieving profitability. This erosion of equity quality suggests that shareholders are bearing the full brunt of the company's aggressive, yet unproven, commercialization strategy.

The reliance on physical assets to support the Proteograph platform indicates a capital-intensive business model that requires significant scale to achieve efficiency. The downward trend in PPE suggests that management may be attempting to preserve cash by limiting further investment in manufacturing or laboratory capacity.